Allelic Variability in the CYP11B2 C344T Single Nucleotide Polymorphism from a Cohort of East Africans by Wright, Spencer
Western Kentucky University
TopSCHOLAR®
Honors College Capstone Experience/Thesis
Projects Honors College at WKU
Spring 5-16-2014
Allelic Variability in the CYP11B2 C344T Single
Nucleotide Polymorphism from a Cohort of East
Africans
Spencer Wright
Western Kentucky University, spencer.wright897@topper.wku.edu
Follow this and additional works at: http://digitalcommons.wku.edu/stu_hon_theses
Part of the Biology Commons
This Thesis is brought to you for free and open access by TopSCHOLAR®. It has been accepted for inclusion in Honors College Capstone Experience/
Thesis Projects by an authorized administrator of TopSCHOLAR®. For more information, please contact connie.foster@wku.edu.
Recommended Citation
Wright, Spencer, "Allelic Variability in the CYP11B2 C344T Single Nucleotide Polymorphism from a Cohort of East Africans" (2014).
Honors College Capstone Experience/Thesis Projects. Paper 490.
http://digitalcommons.wku.edu/stu_hon_theses/490
 
 
ALLELIC VARIABILITY IN THE CYP11B2 C344T SINGLE NUCLEOTIDE 
POLYMORPHISM FROM A COHORT OF EAST AFRICANS 
 
 
 
A Capstone Experience/Thesis Project 
 
Presented in Partial Fulfillment of the Requirements for  
 
the Degree Bachelor of Science with 
 
Honors College Graduate Distinction at Western Kentucky University 
 
 
 
By 
 
Spencer Wright 
 
***** 
 
 
 
 
Western Kentucky University 
2014 
 
 
 
CE/T Committee: 
             Approved by 
Dr. Nancy Rice, Advisor 
 
Dr. Jarrett Johnson                          __________________ 
                 Advisor  
Allison Smith              Department of Biology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by 
Spencer Wright 
2014
 
 
ii 
ABSTRACT 
 
 
 
 
Non-communicable disease (NCD), in particular cardiovascular disease, is a 
significant problem in developing countries.  Essential hypertensions (EH) is a leading 
risk factor for vascular disease and while managing EH in developing countries is 
considered a high global priority, few studies exist from third world populations.  From a 
cohort of Kenyans living in the Kasigau region, we have investigated the allele frequency 
of a single nucleotide polymorphism (SNP) previously reported to correlate with salt-
sensitive EH.  The SNP being investigated is aldosterone synthase CYP11B2 C344T 
(rs1799998), a polymorphism in the renin-angiotensin system (RAS).  The C344T 
polymorphism is located in the promoter region of CYP11B2 and affects the production 
of aldosterone.  In this study the overall allele frequency of T=0.81 and C=0.19, and the 
genotype frequency was T/T=0.66, T/C=0.30, and C/C=0.04 for the total Kasigau 
population in this study.  There was no significant variance in blood pressure among any 
of the three genotype.   
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
In 2008 the World Health Organization estimated that over 36 million deaths 
occurred worldwide from non-communicable diseases (NCD).  Out of the 57 millions 
deaths that occurred worldwide, NCD were the leading cause of mortality at 63% (World 
Health Organization, 2011).  NCDs are diseases that cannot be transmitted from person to 
person and include, cardiovascular disease (CVD), cancer, chronic respiratory disease, 
stroke, and diabetes.  NCD has been known to be the leading cause of pre-mature death in 
people under 60 years old.  In lower-middle-income countries NCD causes 28% of the 
deaths of people under 60 years old, and in lower-income countries it causes 41% of the 
pre-mature deaths under 60.  One of the risk factors associated with NCD is essential 
hypertension (EH) (World Health Organization, 2011). 
EH is defined as high blood pressure without a known cause (Messerli & 
Williams, 2007).  EH is a worldwide concern because of its high frequency and link with 
CVD (Kearney et al., 2005).  EH has been found to be the leading risk factor for CVD 
(Kobubo, 2014).  Of the 39 million people that died of a NCD in 2008, 48% of those 
deaths were linked to CVD (World Health Organization, 2011).   
There are varying stages of hypertension classified as normotensive, pre-
hypertension, stage 1 hypertension, and stage 2 hypertension.  Blood pressure consists of 
a systolic (resulting from ventricular contraction) measurement and diastolic (ventricular 
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relaxation) measurement, which is quantified in mmHg.  Normal blood pressure is less 
than or equal to 120/80 mmHg.  Pre-hypertensive individuals have a blood pressure 
between 121/81-139/89 mmHg.  Stage 1 hypertension is classified as 140/90-159/99, and 
stage 2 hypertension is classified as anything greater than 160/100.  There is a direct 
relationship between an increase in blood pressure and a greater risk for CVD. 
EH is a complex polygenic disease that has been linked to many environmental 
and hereditary factors in humans (Doris, 2002).  Studies have shown that hypertension 
has been connected to a collection of single nucleotide polymorphisms (SNPs) (Doris, 
2002 & Kumar et al., 2003).  A SNP is a common single nucleotide variation in the DNA 
sequence of species. It has been found that single nucleotide variation can alter a person’s 
susceptibility to hypertension (Doris, 2002).   
When a polymorphism or SNP is identified it is referenced with a SNP ID, rs 
number.  An rs number is defined as a variation at a location on an ideal reference 
chromosome and archived in the Single Nucleotide Polymorphism Database (dbSNP).  
The database was developed and managed by the National Center for Biotechnology 
Information of the National Institutes of Health.  The specific SNP in this study is the 
CYP11B2 C344T (rs1799998), which has been linked to EH in humans in other studies 
(Kumar et al., 2003).  CYP11B2 is an aldosterone synthase in the renin-angiontensin 
system (RAS) (Kumar et al., 2003).   
RAS is the key hormonal system in the body responsible for regulating blood 
pressure and sodium homeostasis (Giner et al., 2000).  It has a series of enzymes and 
genes that are found throughout the body that can lead to elevating blood pressure (Figure 
1).  Angiotensinogen is secreted from the liver and broken down to angiotensin 1 by 
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renin, and then converted to angiotensin II by angiotensin converting enzyme (ACE).  
Angiotensin II is responsible for numerous physiological effects including the secretion 
of hormone aldosterone from the adrenal cortex. Aldosterone in the RAS has been found 
to control the reabsorption of ions and water in the kidney.  As reabsorption of ions and 
water increases blood pressure eventually resulting in hypertension.  The C344T 
polymorphism is located in the promotor region of the CYP11B2 gene and affects 
aldosterone production because the gene encoder aldosterone synthase catalyzes the final 
step in aldosterone biosynthesis (Kumar et al., 2003). 
 
Figure 1: Renin-angiontensin system.  The arrows indicate the hormonal pathway that can lead to 
hypertension through Angiontensin II controlling the release of Aldosterone (Public Domain) 
 
This study is based in Kenya, a sub-Saharan country in east Africa, with a 
population of approximately 43 million people (World Health Organization, 2012).  
About 75-80% of Kenyans live in a rural area on less than one US dollar per day (Unicef, 
2014).  The Kenyan health care system is a pyramid-like structure with only two national 
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referral hospitals.  The rest of the country is divided into districts that have a few district-
level hospitals and provincial clinics.  Rural health centers and dispensaries provide most 
of the primary health care (Figure 2).  The health care system is government run by the 
Ministry of Health and the Ministry of Public Health & Sanitation. On average there are 
18 doctors per 100,000 people within the country (The World Health Organization, 
2011).  This is drastically different from the United States with on average 242 doctors 
per 100,000 people (The World Health Organization, 2011).   
 
  
Figure 2: Healthcare infrastructure in Kenya (Williams, 2012) 
This study takes place in Kasigau, Kenya.  Kasigau is located in the Taita-Taveta 
District of southern Kenya.  Kasigau is further divided into three sub-locations and seven 
total villages (Figure 3).  Sub-location Rukanga contains 29% of the population, and it 
includes four villages: Rukanga, Jora, Ngambenyi, and Bungule.  Sub-location 
Makwasinyi makes up 21% of the total population spread across three villages: 
Makwasinyi, Kisimenyi, and Kiteghe.  The third sub-location is Buguta, which contains 
50% of the Kasigau population (Census data, 2009).  It has been found that through 
previous research in our lab that there is a high prevalence of EH in Kasigau, Kenya 
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compared to populations in the United States (Figure 4) (Williams, 2012; Wright et al., 
2011). 
 
Figure 3: Kasigau, Kenya Sub-Locations (http://www.kids4kenya.org/TheSchools.php) 
 
Through Western Kentucky University’s Partners in Caring: Medicine in Kenya 
(PiC:MiK) program the health care concerns of hypertension within the Kasigau area are 
met.  PiC:MiK is a partnership between the people of Kasigau, Kenya and Western 
Kentucky University.  A team of approximately 20 people (3 doctors, 14 students, 1 
faculty member, and 2 volunteers) travel to Kenya for two weeks to conduct medical 
clinics and health care education through sustainable techniques and community oriented 
work.  PiC:MiK also offers the pre-professional students on the trip a first hand global 
view of health care in a developing country.  The 2014 visit was the sixth visit to Kenya 
by this program in the last seven years.  This thesis is a component of the research that is 
focused on the cardiovascular health of the Kasigau people. 
 
 
6 
The goal of this research project is to evaluate the prevalence of one SNP 
(CYP11B2 C344T (rs1799998)) and its correlation to an increased risk of EH in Kasigau, 
Kenya.  It was hypothesized that the high prevalence of observed EH in Kasigau may be 
linked to the CYP11B2 C344T polymorphism. This study will provide key genetic 
information that will help prevent, treat, and/or control hypertension in Kenya and other 
sub-Saharan countries.  
 
 
Figure 4:  EH Distribution in Kasigau, Kenya:  The pie graph on the left shows the values for 
systolic blood pressure, and the pie graph on the right shows the values for the diastolic blood 
pressure. (Williams, 2012)  
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CHAPTER 2 
 
 
MATERIALS AND METHODS 
 
 
Compliance/Informed Consent 
 This study was approved by Western Kentucky University’s Human Subjects 
Review Board (Hr-174, Appendix A) and the Taita District Health Officer in Kenya 
(Appendix B).  All participants were read an informed consent document and their 
willingness to participate in the study implied their consent (Appendix C).  
 
Study Participants 
Participants for this study were selected using a cross-sectional population 
assessment of the Kasigau, Kenya using census data of the region.  The area was 
subdivided into sublocations:  Rukanga, Makwasinyi, and Bughuta which comprise 29%, 
21%, and 50% of the total population, respectively.  Each sublocation includes one to 
four villages in the Kasigau area. 
Each participant was between the ages of 45-75 because of the increased risk of 
EH in this age group.  The goal was to have 50% of participants to be male and 50% of 
participants to be nonpregnant females.   However, 66% of the participants were female 
and 34% were males.  Overall, 400 individuals were recruited to take part in the study, 
although only 161 of those individuals participated in the study.  
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Buccal Cell Acquisition 
 Buccal cells were acquired from participants using Isohelix DNA Buccal Cell 
Swabs.  These swabs were excellent to collect human genomic DNA because they can 
yield up to 5 µg of DNA.  The swabs were labeled by village and participants number in 
order to correlate genotype data to an individual’s demographic data. 
 The collection of the buccal cells occurred during the participant’s clinic visit.  
The individual’s cheek was swabbed thoroughly for one minute, and then the swabs were 
sealed to avoid contamination.  The samples were stored at 4
o
C until the DNA was 
isolated. 
  
Genomic DNA Isolation 
 Genomic DNA was isolated from swabs by standard alkaline lysis using the 
QIAamp DNA Mini Kit (Qiagen; Valencia, CA, USA).  Briefly, swabs were submerged 
in phosphate buffered saline (PBS) in a microcentrifuge tube.  Proteinase K and Buffer 
AL were added and the samples were immediately vortexed for fifteen seconds to ensure 
efficient lysis.  Proteinase K was selected as the optimal enzyme with the lysis buffer 
(Qiagen; Valencia, CA, USA).  The samples were incubated at 56
o
C for ten minutes, 
which activated the protease within each sample. 
 Subsequently ethanol (96-100%) was added to each sample, vortexed to ensure 
proper mixing, then pipetted onto a spin column from the QIAamp DNA Mini Kit, and 
centrifuged at 6,000 g, 1 minute to isolate genomic DNA.  Columns were washed and 
centrifuged with a series of wash buffers (AW1 and AW2) provided in the kit.  The DNA 
was extracted from the spin columns by the addition of buffer AE, by heating to 60
o
C.  
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The columns were left to incubate with buffer AE in the tube for five minutes before they 
were centrifuged at 6,000 g for one minute. The elution step was performed twice to 
increase DNA yield.  The two sets of DNA from each sample were stored at -20
o
C.  All 
genomic DNA was isolated from samples prior to quantification.  
 
Nanodrop Analysis 
 DNA concentration and purity were determined by the ratio of absorbance of UV 
light at 260/280 nm using a Nanodrop spectrophotometer (Thermo Scientific; 
Wilmington, DE, USA).  Two µl of each sample was analyzed to determine the final 
DNA concentration.   
 
Allelic Discrimination Analysis 
 Quantitative Polymerase Chain Reaction (Q-PCR) was used for genotype and 
allelic discrimination, specifically by using the Taqman SNP Genotyping Assay Protocol 
(Applied Biosystem; Foster City, CA, USA).  This assay uses fluorescent dyes to 
determine DNA binding.  Each dye is covalently attached to a primer used in the PCR 
reaction.  A blue dye, 6FAM indicates the fluorescence of the G allele in the SNP.  The 
green dye, VIC indicates the fluorescence of the A allele in the SNP.  Sequence Detection 
System (SDS) software allowed the identification of the blue or green fluorescence 
(Applied Biosystems; Foster City, CA, USA).  A reporter dye and a quencher dye are 
also found within the assay (Figure 5). 
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Figure 5:  Taqman® genotyping assay. (“Taqman® Genotyping Assay Product Bulletin,” Applied 
Biosystems; Foster City, CA, USA). 
 
 All samples were run in triplicate on a MicroAmp® Optical 96-well reaction plate 
(Applied Biosystems; Foster City, CA, USA) in an Applied Biosystem Prism 7300 Real-
Time polymerase chain reaction instrument.  On each plate a negative control was 
included that lacked DNA.  
 Each assay included 12.5 µl of a premade master mix, 1.25 µl of SNP assay, 
11.25 µl of DNA and water, as well as 50 nM of forward primer labeled with VIC dye, 
50 nM of reverse primer labeled with FAM dye, deoxyribonucleotides with deoxyuridine 
triphosphates, AmpliTag Gold DNA polymerase, AmpErase® uracil-N-glycosylase, 
optimized buffer, and passive reference components.  The SNP’s context sequence is 
provided in the table below. 
SNP  Context Sequence 
CYP11B2 
rs1799998 
TTTATCTTATCGTGAGATGAGAGGG[A/G]GCCTTGGATTCTTTTAA
TAGACTTT 
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The cycling conditions were as follows: activation (95
o
C-10 minutes), denaturing (92
o
C-
15 seconds), extending and annealing (60
o
C-70 seconds).  The cycling procedure was 
repeated 50 times and was performed to sufficiently elevate the fluorescence for SDS to 
detect within each well.  
Fluorescence intensity for each sample was quantified through Q-PCR.  Allele T 
or C was determined based upon the values given from the fluorescence intensity.  
Values below the no template control were eliminated from analysis.  
 
Statistical Analysis 
 The Hardy-Weinburg Equilbrium (HWE) equation was used to determine if the 
genotype and allelic frequencies observed were affected by any evolutionary influences.  
The expected values of alleles were derived from observed data and analyzed using the 
HWE equation (p
2
+2pq+q
2
=1).  The p
2
 equals the frequency of the genotype T/T, the p 
equals the frequency of allele T, the q
2
 equals the frequency of the genotype C/C, and the 
q equals the frequency of allele C. 
 The genotype frequencies analyzed using a Pearson’s Chi Square test.  The 
equation  was used to determine significance of deviation in the genotype 
frequencies and the HWE models.  A Chi Square value was calculated in order to 
determine if a frequency from each sublocation and in each hypertension classification 
fell within HWE.  
 Variance of systolic blood pressure for each genotype was assessed by Kruskal-
Wallis one way Analysis of Variance on Ranks using Sigma Plot software.  
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CHAPTER 3 
 
 
RESULTS 
 
 
 As a whole, approximately 81% of the Kasigau population possess the T allele, 
while 19% possess the C allele of the CYP11B2 C344T SNP (Figure 6).  Per sublocation 
the C allele ranged from 13%-23% with Buguta having the lowest frequency. When the 
allele frequencies were assessed as a genotype, it was found that Kasigau displayed 66% 
T/T, 30% C/T, and 4% T/T (Figure 7).  Makwasinyi had the highest distribution of C/C at 
10%. 
 To assess whether allelic frequency varied based on the severity of EH, the 
derived allelic and genotypic distribution of the SNP was determined for normotensive, 
pre-hypertensive, Stage I EH, and Stage II EH, for the total Kasigau population as well as 
the three sublocations.  The EH classification was determined by using only the systolic 
BP of participants. When the obtained genotype frequencies of the C344T SNP were 
compared to the expected frequencies predicted by the HWE, all alleles were found to be 
in HWE with the exception of pre-hypertensive people from Makwasinyi, (χ²=8.00, 
p=0.04).   
For all the sublocations and EH classifications T alleles were in greater frequency 
than C alleles (Table 1).  The T allele frequency for Kasigau as a whole, Buguta, 
Makwasinyi, and Rukanga ranged from 78%-87%, while the C allele frequency ranged 
from 13%-22%.  The majority of the participants in the study had a genotype of T/T.  
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When variance in systolic blood pressure was analyzed among the three different 
genotypes there was no significant difference among them, as determined by the 
ANOVA, (p=0.78) (Table 2).  The difference in the median values among the treatment 
groups is not great enough to exclude the possibility that the difference is due to random 
sampling variability.  However, variance was not analyzed based on EH stage. 
 Based upon the results, the majority of the people of Kasigau possess the T allele 
of the CYP11B2 C344T SNP.  There is small variability in the frequency of the alleles 
with the Kasigau participants who are normotensive vs the participants who have some 
form of hypertensive.  More statistical analysis will need to be done to confirm these 
results.  
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Figure 6:  CYP11B2 allele frequencies for Kasigau 
 
 
 
 
 
Figure 7:  CYP11B2 genotype distribution for Kasigau 
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Table 1: CYP11B2 genotype distribution and allele frequencies per EH classification in Kasigau. HWE, 
Hardy-Weinburg Equilibrium. *=p<0.05 
 
Rukanga Genotype Normotensive Pre-hypertensive Type 1 EH Type 2 EH 
N=48 T/T 6 10 5 8 
 T/C 2 6 5 4 
 C/C 1 0 1 0 
 HWE χ²=1.15 
p=0.28 
χ²=0.85 
p=0.36 
χ²=0.02 
p=0.87 
χ²=0.48 
p=0.49 
 Allele Normotensive Pre-hypertensive Type 1 EH Type 2 EH 
 T 14 26 15 20 
 C 3 6 6 4 
 f (T) 
f (C) 
0.82 
0.18 
0.81 
0.19 
0.71 
0.29 
0.83 
0.17 
Makwasinyi Genotype Normotensive Pre-hypertensive Type 1 EH Type 2 EH 
N=31 T/T 0 7 5 11 
 T/C 0 0 3 2 
 C/C 0 1 1 1 
 HWE χ²=ND 
p=ND 
χ²=8.00 
p=0.04* 
χ²=0.26 
p=0.61 
χ²=2.43 
p=0.12 
 Allele Normotensive Pre-hypertensive Type 1 EH Type 2 EH 
 T 0 14 13 24 
 C 0 2 5 4 
 f (T) 
f (C) 
0.00 
0.00 
0.88 
0.13 
0.72 
0.28 
0.86 
0.14 
Bughuta Genotype Normotensive Pre-hypertensive Type 1 EH Type 2 EH 
N=26 T/T 3 9 5 3 
 T/C 0 3 1 1 
 C/C 0 1 0 0 
 HWE χ²=ND 
p=ND 
χ²=0.86 
p=0.35 
χ²=0.05 
p=0.82 
χ²=0.08 
p=0.77 
 Allele Normotensive Pre-hypertensive Type 1 EH Type 2 EH 
 T 6 21 11 7 
 C 0 5 1 1 
 f (T) 
f (C) 
1.00 
0.00 
0.81 
0.19 
0.92 
0.08 
0.88 
0.13 
Kasigau Genotype Normotensive Pre-hypertensive Type 1 EH Type 2 EH 
N=105 T/T 9 26 15 22 
 T/C 2 9 9 7 
 C/C 1 2 2 1 
 HWE χ²=1.92 
p=0.17 
χ²=0.95 
p=0.33 
χ²=0.15 
p=0.69 
χ²=0.22 
p=0.64 
 Allele Normotensive Pre-hypertensive Type 1 EH Type 2 EH 
 T 20 61 39 51 
 C 4 13 13 9 
 f (T) 
f (C) 
0.83 
0.17 
0.82 
0.18 
0.75 
0.25 
0.85 
0.15 
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Table 2: Variance in systolic blood pressure among genotype groups; H = 0.497 with 2 degrees of 
freedom.  (P = 0.780) 
 
Group N Median 
T/T 73 140.00 
T/C 30 144.00 
C/C 7 139.00 
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CHAPTER 4 
 
 
DISCUSSION 
 
 
In this study, the allelic and genotype frequencies of the CYP11B2 C344T SNP 
known to influence predisposition to EH, was evaluated from a population in rural 
Kasigau, Kenya.  The allele frequencies were compared across normotensive, 
prehypertensive, Stage I hypertensive, and Stage II hypertensive.  Hypertension was 
measured using only the participants’ systolic blood pressure.  Overall, this work 
investigates how polymorphic variation in a RAS gene influences phenotypic differences 
of EH in Kasigau, Kenya. 
There are many different approaches that exist for studying genetic associations 
of complex diseases including genome-wide association studies, linkage disequilibrium, 
and pooling strategies (Binder, 2006).  The target gene approach was used in this study 
because SNPs in the RAS genes have already been shown in other populations to 
specifically correlate with an increase in susceptibility to EH (Tabor et al., 2002).   
In our study all of the sublocation/EH classifications were found to be in HWE 
except for the pre-hypertensive people from Makwasinyi, (χ²=8.00, p=0.04). These 
results likely reflect limiting sample size although non-random mating may also be 
contributing.  This may be due to the physical location of this village on the opposite side 
of the Kasigau Mountain, which contributes to its geographic isolation. 
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It has been found in many studies that the CYP11B2 C344T SNP is associated 
with EH, but there are differences regarding which allele is the susceptible allele 
(Sookoian et al., 2007; Kumar et al., 2003; Tiago et al., 2003).  Kumar’s research study 
found that the C allele is the susceptible allele for EH in a Caucasian population.  The 
study also found that in participants who had both the C allele and EH, greater than 50% 
were C/C homozygous.  This was found to be significant for women who had EH (Kumar 
et al., 2003).  In the current study, the gender of the participants was not taken into 
account during the analysis, although 56 of the participants had Stage I or Stage II 
Hypertension.  Out of those 56 participants 16 had the genotype T/C and 3 had the C/C 
genotype. If a larger sample size were available it is possible that a greater amount of the 
susceptible C allele may be present.   
In contrast, a different study found that the T allele was correlated with an 
increase in EH in people who were of African ethnicity (Tiago et al., 2003).  In Tiago’s 
(2003) study, it was also found that the T allele is more present in a South African 
population.  Sixty-six percent of participants in the current study had the T/T genotype. 
Our study also showed that 88% of participants with the T/T genotype and 83% of 
participants with the C/C genotype had EH.  Taking into account that all the participants 
in this study are of African ethnicity our data supports the conclusion of Tiago, et al 
(2003).  However, further research should be done to determine the genetic variation in 
South Africans and East Africans.  It should be noted that the ancestral allele is the T 
allele.  Most of the participants in our study with a form of EH had the T allele, however 
there is no evidence to disregard the C allele as the susceptible allele. If a larger sample 
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size were available it is possible that a greater amount of the susceptible C allele may be 
present.   
This study is one of the first to research a SNP related to EH in East Africans 
(Freeman, 2013).  The results in the future will be used to help promote awareness and 
treatment for hereditary factors causing CVD and EH in developing countries.  This study 
also gave insight into how the genetic components of the RAS potentially affect the 
development of EH in Kasigau, Kenya.  Future research will also include epigenetic 
factors, gene-gender interactions, aging effects, and salt sensitivity, which all have been 
shown to be linked to EH in other studies (Deng, 2007; Hendriks et al., 2012). 
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